Teknoloji Yatırımları ve Danışmanlık Sanayi ve Ticaret

Turgut Biotech, operating under the corporate entity Teknoloji Yatırımları ve Danışmanlık Sanayi ve Ticaret A.Ş., is a prominent Turkish biotechnology company focused on the development and manufacture of biosimilar monoclonal antibodies. The company was established by the Turgut family to spearhead high-tech pharmaceutical production in Turkey following the sale of their previous generic pharmaceutical business. Turgut Biotech operates a state-of-the-art R&D center and a GMP-certified manufacturing facility in the Istanbul region, utilizing advanced single-use bioreactor technologies. Their product pipeline is centered on high-value biologics for oncology and autoimmune diseases, with a portfolio featuring biosimilars for rituximab, trastuzumab, and bevacizumab. Through a strategic partnership with Lonza, the company employs the GS Xceed Gene Expression System to ensure their products meet international quality and regulatory standards. The organization plays a central role in Turkey's strategic initiative to localize the manufacturing of complex biopharmaceuticals and reduce dependency on imports.